Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 26;13(12):1641.
doi: 10.3390/brainsci13121641.

The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review

Giulio Longo  1 , Angelica Cicolini  1 , Laura Orsolini  1 , Umberto Volpe  1
Affiliations
Review

The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review

Giulio Longo et al. Brain Sci. .

Abstract

Lumateperone (also known as ITI-007 or ITI-722) represents a novel second-generation medication characterized by a favorable safety and tolerability profile. This is attributed to its notable selectivity for D2 receptors within specific regions of the brain. The U.S. Food and Drug Administration (FDA) granted approval for the treatment of schizophrenia in adults in December 2019. Additionally, it gained approval for addressing depressive episodes associated with bipolar I and II disorders in adults, either as a standalone therapy or in conjunction with lithium or valproate, in December 2021. The objective of this investigation is to systematically review the existing literature to assess the safety, tolerability, and efficacy of lumateperone in the treatment of schizophrenia. Lumateperone has demonstrated effectiveness in addressing positive, negative, and cognitive symptoms associated with schizophrenia. The evaluation of safety indicators in the reviewed studies indicates that lumateperone is deemed to be a well-tolerated and safe antipsychotic. Additional research is warranted to explore lumateperone's efficacy in managing major depressive disorders, behavioral issues in Alzheimer's disease and dementia, sleep maintenance insomnia, bipolar disorders, and personality disorders.

Keywords: ITI-007; ITI-722; antipsychotics; lumateperone; novel antipsychotics; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as potential conflicts of interest.

Figures

Figure 1
Figure 1
Chemical structure of lumateperone.
Figure 2
Figure 2
Flowchart illustrating the process of study search and selection in accordance with PRISMA guidelines.
See this image and copyright information in PMC

References

    1. Davis R., Correll C.U. ITI-007 in the treatment of schizophrenia: From novel pharmacology to clinical outcomes. Expert. Rev. Neurother. 2016;16:601–614. doi: 10.1080/14737175.2016.1174577. - DOI - PubMed
    1. Greenwood J., Acharya R.B., Marcellus V., Rey J.A. Lumateperone: A Novel Antipsychotic for Schizophrenia. Ann. Pharmacother. 2021;55:98–104. doi: 10.1177/1060028020936597. - DOI - PubMed
    1. Mazza M., Marano G., Traversi G., Sani G., Janiri L. Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders. CNS Neurol. Disord. Drug Targets. 2020;19:243–247. doi: 10.2174/1871527319666200601145653. - DOI - PubMed
    1. Reddy H.M., Poole J.S., Maguire G.A., Stahl S.M. New Medications for Neuropsychiatric Disorders. Psychiatr. Clin. N. Am. 2020;43:399–413. doi: 10.1016/j.psc.2020.02.008. - DOI - PubMed
    1. Blair H.A. Lumateperone: First Approval. Drugs. 2020;80:417–423. doi: 10.1007/s40265-020-01271-6. - DOI - PubMed

LinkOut - more resources